Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordan Amdahl

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Oncology and Therapy|March 7, 2017
Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic MelanomaJordan Amdahl, Lei Chen, Thomas E Delea
Infectious Diseases and Therapy|November 10, 2020
Pediatric Vaccines and Cost-Effectiveness Thresholds: How Much is Too Much to Pay for Prevention?Jordan Amdahl, Derek Weycker, Ray Farkouh, et al.
Pharmacoeconomics|December 10, 2014
Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in CanadaThomas E Delea, Jordan Amdahl, Alice Wang, et al.
Journal of Managed Care & Specialty Pharmacy|January 7, 2015
Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United StatesThomas E Delea, Jordan Amdahl, Jose Diaz, et al.
Plos One|June 22, 2017
Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United KingdomJordan Amdahl, Jose Diaz, Arati Sharma, et al.
Journal of Managed Care & Specialty Pharmacy|November 6, 2015
The Authors RespondThomas E Delea, Jordan Amdahl, Jose Diaz, et al.
Pharmacoeconomics|June 21, 2019
Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United StatesThomas E Delea, Xinke Zhang, Jordan Amdahl, et al.
Sarcoma|July 16, 2014
Cost-effectiveness of pazopanib in advanced soft tissue sarcoma in the United kingdomJordan Amdahl, Stephanie C Manson, Robert Isbell, et al.
International Journal of Radiation Oncology, Biology, Physics|October 15, 2017
Cost-Effectiveness of Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer Using Evidence From the Chest Radiotherapy Extensive-Stage Small Cell Lung Cancer Trial (CREST)Grace I Patrice, Nataniel H Lester-Coll, James B Yu, et al.
Journal of Medical Economics|June 21, 2017
Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspectiveThomas E Delea, Jordan Amdahl, Diana Boyko, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Oncology and Therapy|March 7, 2017
Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic MelanomaJordan Amdahl, Lei Chen, Thomas E Delea
Infectious Diseases and Therapy|November 10, 2020
Pediatric Vaccines and Cost-Effectiveness Thresholds: How Much is Too Much to Pay for Prevention?Jordan Amdahl, Derek Weycker, Ray Farkouh, et al.
Pharmacoeconomics|December 10, 2014
Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in CanadaThomas E Delea, Jordan Amdahl, Alice Wang, et al.
Journal of Managed Care & Specialty Pharmacy|January 7, 2015
Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United StatesThomas E Delea, Jordan Amdahl, Jose Diaz, et al.
Plos One|June 22, 2017
Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United KingdomJordan Amdahl, Jose Diaz, Arati Sharma, et al.
Journal of Managed Care & Specialty Pharmacy|November 6, 2015
The Authors RespondThomas E Delea, Jordan Amdahl, Jose Diaz, et al.
Pharmacoeconomics|June 21, 2019
Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United StatesThomas E Delea, Xinke Zhang, Jordan Amdahl, et al.
Sarcoma|July 16, 2014
Cost-effectiveness of pazopanib in advanced soft tissue sarcoma in the United kingdomJordan Amdahl, Stephanie C Manson, Robert Isbell, et al.
International Journal of Radiation Oncology, Biology, Physics|October 15, 2017
Cost-Effectiveness of Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer Using Evidence From the Chest Radiotherapy Extensive-Stage Small Cell Lung Cancer Trial (CREST)Grace I Patrice, Nataniel H Lester-Coll, James B Yu, et al.
Journal of Medical Economics|June 21, 2017
Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspectiveThomas E Delea, Jordan Amdahl, Diana Boyko, et al.
Pageof 1